April 22 (Reuters) – AbbVie will invest $1.4 billion to build a manufacturing campus in North Carolina, the drugmaker said on Wednesday, marking its biggest investment to date in a single site.
The campus will serve as AbbVie’s main U.S. hub for injectable drug manufacturing, supplying medicines domestically and abroad as the company expands production capacity in the country.
• Spread across 185 acres in Durham, North Carolina, the facility will make medicines to treat immune system diseases, cancer and brain and nerve disorders.
• AbbVie plans to hire 734 employees over four years for the campus, including engineers, scientists and manufacturing staff.
• Construction on the project is expected to start in 2026 and be completed by the end of 2028, supporting more than 2,000 construction jobs.
• The first phase will include manufacturing plants, laboratories, a warehouse, office space and employee facilities.
• The drugmaker had in February said it would invest $380 million to build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago, Illinois campus, expanding U.S. production of neuroscience and obesity medicines.
• The new North Carolina project is part of AbbVie’s plan to spend about $100 billion on U.S. research, development and manufacturing over the next decade.
• The company has committed more than $2.2 billion over the past year for manufacturing projects in the country.
(Reporting by Sahil Pandey in Bengaluru; Editing by Jonathan Ananda)
Comments